ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1425

Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort

Pankti Mehta1, Shangyi Gao2, Virginia Carrizo Abarza3, Fadi Kharouf4, Dafna D. Gladman5, Vinod Chandran6 and Denis Poddubnyy7, 1University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, 2Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, 3University of Toronto, Toronto, 4University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany

Meeting: ACR Convergence 2025

Keywords: Damage Index, Patient reported outcomes, Psoriatic arthritis, radiography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is limited quantitative data on how radiographic damage impacts PF in PsA. This study aimed to assess the relationship between radiographic damage and PF in PsA patients.

Methods: We analyzed data from a large, prospectively enrolled cohort of PsA patients followed since 1978. Assessments were performed every six months, including evaluations of disease activity, patient-reported outcomes, and treatment details. Radiographs were obtained every two years. Disease activity was measured by swollen joint count (SJC), and PF was assessed using the Health Assessment Questionnaire (HAQ; 0-3) and the Short Form 36 (SF-36) PF domain score (0-100). Radiographic damage was scored using the modified Steinbrocker scoring system (mSS, 0-168). Only patients with PF data collected within three months of their radiographs were included in the analysis.Baseline characteristics at enrollment were summarized. Cumulative probability plots were created to illustrate visit-to-visit changes in both mSS scores and PF scores. Multivariable linear mixed models (LMM) were used to examine the association between PF measures (HAQ and SF-36 PF) and mSS, adjusting for covariates including age at PsA diagnosis, disease activity (SJC at the time of radiographs), sex, and disease duration. Further, we assessed the severity of joint damage (any joint graded 2, 3, or 4) and the number of severely damaged joints (graded 2, 3, or 4) per patient for their association with SF-36 PF using LMM, adjusting for SJC, age at PsA diagnosis, sex, and disease duration.

Results: Among 1,177 patients, the mean age at enrollment was 44.61 ± 12.76 years, and 657 (55.8%) were male. The median mSS was 2 (IQR 0, 8.5), HAQ was 0.62 (IQR 0.12, 1.12), and SF-36 PF score was 60 (IQR 35, 85) at enrollment. The mSS change scores in relation to the corresponding HAQ and SF-36 PF change scores are presented in Figure 1.The mSS showed significant associations with both HAQ (b = 0.003, 95% CI 0.002 to 0.004) and SF-36 PF (-0.10; 95% CI -0.15 to -0.05), after adjusting for disease activity (SJC), age at PsA diagnosis, sex, and disease duration (Table 1). While the presence of a damaged joint was not significantly associated with PF, the number of severely damaged joints (graded 2, 3, or 4) per patient was significantly associated with both HAQ (b = 0.01, 95% CI 0.001 to 0.01) and SF-36 PF (-0.22, 95% CI -0.37 to -0.07).

Conclusion: Structural damage, as quantified by the mSS , is significantly associated with physical function in PsA, independent of disease activity and other factors. Specifically, a one-unit increase in the mSS corresponds to a 0.003 increase in HAQ and 0.10 decrease in SF-36 PF. While the presence of a single damaged joint does not notably affect PF, the cumulative number of severely damaged joints is significantly associated with a decline in PF. These findings underscore the importance of early diagnosis and effective management of PsA to preserve physical function and prevent structural damage.

Supporting image 1Figure 1: Cumulative probability plots reflecting visit-to-visit change scores of the modified Steinbrocker score with SF-36 PF (A) and HAQ (B)

Supporting image 2Table 1: Association between mSteinbrocker score and physical function using multivariable linear mixed models


Disclosures: P. Mehta: None; S. Gao: None; V. Carrizo Abarza: None; F. Kharouf: None; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, 5, Eli Lilly, 2, 5, Janssen, 5, Johnson & Johnson, 2, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, UCB, 2, 5; V. Chandran: AbbVie/Abbott, 1, 5, AstraZeneca, 12, Spousal employment, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 1, 5, Fresenius Kabi, 2, Janssen, 1, 5, 6, Novartis, 1, UCB, 1; D. Poddubnyy: AbbVie, 2, 5, 6, Biocad, 2, BMS, 6, Eli Lilly, 2, 5, 6, Gilead, 2, GSK, 2, Moonlake, 2, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Samsung Bioepis, 6, UCB, 2, 6.

To cite this abstract in AMA style:

Mehta P, Gao S, Carrizo Abarza V, Kharouf F, Gladman D, Chandran V, Poddubnyy D. Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/quantifying-functional-impact-of-structural-damage-in-psoriatic-arthritis-insights-from-a-long-term-prospective-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quantifying-functional-impact-of-structural-damage-in-psoriatic-arthritis-insights-from-a-long-term-prospective-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology